Parabolic Drugs Limited Announces Executive Changes

Parabolic Drugs Limited is a holding company. The Company is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates. It is engaged in the manufacture of pharmaceuticals, medicinal chemical and botanical products. Its products and services include Cefuroxime Axetil Amorphus and Ceftriaxone Sodium Sterile. Its product portfolio includes Oral and Sterile Semi Synthetic Penicillin API, Oral and Sterile Cephalosporin API in antibiotic segment to non-antibiotic API in the Cardiovascular, Nonsteroidal anti-inflammatory drugs (NSAID), Anti-Hypertensive and Osteoporosis segments. Its products include Cefixime Trihydrate, Ceftibuten, Cefcapene Pivoxil, Cefuroxime Sodium, Amoxycillin Trihydrate, Bacampicillin Hcl, Piperacillin Sodium, Sulbactum Sodium, Deferasirox, Pentazocine, Raubasine, Yohimbine, Montelukast, Vildagliptin, Cefoxitin Sodium and Cefpodoxime Acid.